Evidence map›Paper›PMID 39658346›Full record

SynthesisBritish journal of clinical pharmacology2025

β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis.

Lujain Ez Eddin, Rebecca Preyra, Fatemeh Ahmadi, Atefeh Jafari, Mohammad Ali Omrani, Flory T Muanda

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lujain Ez EddinICES Western, London, ON, Canada.
Rebecca PreyraDepartment of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Fatemeh AhmadiICES Western, London, ON, Canada.
Atefeh JafariICES Western, London, ON, Canada.
Mohammad Ali OmraniICES Western, London, ON, Canada.ORCID https://orcid.org/0000-0001-6847-0699
Flory T MuandaICES Western, London, ON, Canada.ORCID https://orcid.org/0000-0003-4682-6564

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis systematic review and meta-analysis aimed to evaluate the association between β-blocker use and neuropsychiatric adverse events, specifically focusing on short-term outcomes.

methodsA comprehensive literature search identified studies reporting neuropsychiatric outcomes in patients using β-blockers, including randomized controlled trials and observational studies. Relative risks (RR) and 95% confidence intervals (CIs) were calculated for outcomes such as dizziness, insomnia, nightmares, drowsiness and delirium.

resultsOur analysis revealed that β-blocker use was significantly associated with an increased risk of dizziness (RR 1.72, 95% CI [1.39-2.14]; I

conclusionsOur findings suggest a significant association between β-blocker use and an increased risk of neuropsychiatric adverse events, particularly insomnia and dizziness with higher risks associated with lipophilic β-blocker use. Given the ambiguity surrounding dizziness and its classification as a neuropsychiatric effect, our findings are exploratory, and we cannot exclude a potential cardiovascular origin for dizziness. Most studies (75%) were published before the CONSORT statement in 1996, indicating potential reporting limitations and a lack of recent research. Additionally, 60% of studies had a high risk of bias, underscoring the need for more rigorous and contemporary investigations into the neuropsychiatric implications of β-blocker use.

Indexed as

Adrenergic beta-AntagonistsMental DisordersDizzinessDreamsHumansObservational Studies as TopicPropranololRandomized Controlled Trials as TopicSleep Initiation and Maintenance DisordersAdrenergic beta-AntagonistsPropranololhydrophilicinsomnialipophilicmeta‐analysisneuropsychiatric adverse effect

Identifiers

PMID39658346
PMCPMC11773113

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.